JP2020533369A5 - - Google Patents

Download PDF

Info

Publication number
JP2020533369A5
JP2020533369A5 JP2020515029A JP2020515029A JP2020533369A5 JP 2020533369 A5 JP2020533369 A5 JP 2020533369A5 JP 2020515029 A JP2020515029 A JP 2020515029A JP 2020515029 A JP2020515029 A JP 2020515029A JP 2020533369 A5 JP2020533369 A5 JP 2020533369A5
Authority
JP
Japan
Prior art keywords
guglusteryl
guglusterol
thymoquinone
phosphatidylcholine
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020515029A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533369A (ja
JP7432501B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/050728 external-priority patent/WO2019055550A2/en
Publication of JP2020533369A publication Critical patent/JP2020533369A/ja
Publication of JP2020533369A5 publication Critical patent/JP2020533369A5/ja
Application granted granted Critical
Publication of JP7432501B2 publication Critical patent/JP7432501B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020515029A 2017-09-12 2018-09-12 チモキノン含有組成物の調製法 Active JP7432501B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762557649P 2017-09-12 2017-09-12
US62/557,649 2017-09-12
PCT/US2018/050728 WO2019055550A2 (en) 2017-09-12 2018-09-12 METHODS FOR PREPARING COMPOSITIONS CONTAINING THYMOQUINONE

Publications (3)

Publication Number Publication Date
JP2020533369A JP2020533369A (ja) 2020-11-19
JP2020533369A5 true JP2020533369A5 (https=) 2021-10-21
JP7432501B2 JP7432501B2 (ja) 2024-02-16

Family

ID=65723858

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020515029A Active JP7432501B2 (ja) 2017-09-12 2018-09-12 チモキノン含有組成物の調製法

Country Status (6)

Country Link
US (2) US11389413B2 (https=)
EP (1) EP3681484A4 (https=)
JP (1) JP7432501B2 (https=)
CA (1) CA3075506A1 (https=)
MX (1) MX2020002730A (https=)
WO (1) WO2019055550A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121752252A (zh) * 2023-08-16 2026-03-27 吉纳制药公司 含有mTOR抑制剂和脂质的组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006506464A (ja) * 2002-07-23 2006-02-23 ニュートリノヴァ ニュートリション スペシャリティーズ アンド フード イングリーディエンツ ゲゼルシャフト ミット ベシュレンクテル ハフツング 食事性繊維およびコレステロール低下物質で造られたコレステロール低下剤
US8029831B2 (en) 2008-07-29 2011-10-04 Bionexus, Ltd. Formulations containing thymoquinone for urinary health
CA2604943C (en) * 2005-04-15 2013-09-17 Clarus Therapeutics, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
WO2007086078A2 (en) 2006-01-30 2007-08-02 Panacea Biotec Ltd. Novel pharmaceutical compositions and process of preparation thereof
WO2008017484A1 (en) * 2006-08-09 2008-02-14 Dsm Ip Assets B.V. Novel agents for the treatment of disorders connected to impaired neurotransmission
JP2010509355A (ja) * 2006-11-06 2010-03-25 ジャイナ ファーマシューティカルズ,インコーポレーテッド グッグルリン脂質の方法および組成物
JP2012518618A (ja) * 2009-02-20 2012-08-16 ディーエスエム アイピー アセッツ ビー.ブイ. 機敏さのためのオレガノ抽出物
KR20150027154A (ko) * 2012-07-02 2015-03-11 디에스엠 아이피 어셋츠 비.브이. 타이모퀴논을 함유하는 캡슐
WO2015086239A1 (en) * 2013-12-09 2015-06-18 Brattström-Junghanns Gbr Thymoquinone composition for treating neurodegenerative diseases
US10245273B2 (en) * 2013-12-26 2019-04-02 Clarus Therapeutics, Inc. Oral pharmaceutical products and methods of use combining testosterone esters with hypolipidemic agents
WO2016005786A1 (en) * 2014-07-11 2016-01-14 Labatec Pharma S.A. Liposomal formulations comprising thymoquinone and taxane, and methods of treating cancer using same

Similar Documents

Publication Publication Date Title
US10357467B2 (en) All-natural enteric soft capsules
RU2492854C2 (ru) Производство быстрорастворимых/распадающихся пленок, содержащих большое количество активных веществ
KR102636273B1 (ko) 플로로글루시놀 및 트리메틸플로로글루시놀의 제약 제제
US20140044784A1 (en) Combined formulation with improved stability
CN101652141A (zh) 他克莫司的调节释放剂型
JP2015120700A (ja) ステロイド組成物
JP2011513391A (ja) ミコフェノラートを含有する徐放性医薬組成物およびその方法
JP2017500332A (ja) 経口医薬組成物
CN101631533B (zh) 含有西洛他唑的控释制剂及其制备方法
US20190231699A1 (en) Controlled-release solid dosage forms of mesalamine
AU2017213852A1 (en) Deuterated domperidone compositions and methods for therapy of disorders
WO2017037647A1 (en) Stable pharmaceutical compositions of abiraterone
TW202038936A (zh) 治療或預防痛風或高尿酸血症之方法
CN113423390A (zh) 阿法比星制剂及其制备方法
US20150118296A1 (en) Controlled release budesonide compositions
CN101854929A (zh) 新型制剂
CN106794149A (zh) 含ω‑3脂肪酸酯和他汀类的口服给药复合制剂
JP2021024865A (ja) アビラテロン酢酸エステル含有製剤
JP2020533369A5 (https=)
TW202302116A (zh) 口服腸溶皮質類固醇的藥物組合物
JP2024515678A (ja) 薬物特異的送達用カプセル及びその調製方法
JPH1025255A (ja) 溶解性の改善された難溶性薬剤
CN101176725A (zh) 辛伐他汀和阿司匹林的稳定剂型
US10517846B2 (en) Pharmaceutical compositions for treating acne
US20210113479A1 (en) Dosage forms for delivery of medicines to the lower gastrointestinal tract